Imagine you bought a fund that promised you a slice of hot private companies like Anthropic and Databricks. Now imagine that fund's stock price just got cut in half in a single day. That's what happened Thursday to shareholders of the Fundrise Innovation Fund (VCX), after activist short seller Andrew Left's Citron Research dropped what can only be described as a brutal takedown.
The stock fell a staggering 49.21%, landing at $193. The cause? A series of critical posts from Citron that didn't just question the fund's math—it questioned its entire reason for being.
The "Simple Math" of a Disconnected Valuation
Citron came out swinging on X, announcing it is short VCX. The core argument is, in their words, "Simple math." They believe the stock's valuation has become completely disconnected from the value of the underlying assets in the fund's portfolio.
To drive the point home, they pointed to a recent, painful example for another fund: Destiny Tech100 Inc. (DXYZ). DXYZ saw a massive premium—we're talking over 1,400%—evaporate even though the companies in its portfolio were doing just fine. The message from Citron was a stark warning about gravity: "gravity is not a theory" when it comes to lofty valuations eventually meeting reality.
Old Scars and New Marketing Questions
But Citron didn't stop at valuation. They dug into the fund's sponsor, Fundrise Advisors LLC, and its regulatory history. They highlighted a 2023 settlement with the U.S. Securities and Exchange Commission where the firm paid $250,000. The SEC found that Fundrise "willfully" violated securities laws by paying more than 200 influencers to promote its products without properly disclosing those payments.
Citron then connected that past to the present. They pointed to a line in the VCX prospectus showing a "0.42%" marketing expense, which works out to roughly $3 million a year. The short seller essentially asked the SEC to take a fresh look: are those current marketing dollars being used to pay for promotions that still aren't being disclosed? It's a question that implies the old habits might not have died.
What's Actually in the Portfolio?
So what does this controversial fund actually own? According to its website, the Fundrise Innovation Fund holds stakes in private unicorns—the kind of companies most retail investors can only read about. Its top holdings are a who's who of tech: Anthropic makes up 20.7% of the portfolio, and Databricks is 17.7%. It also holds positions in OpenAI and SpaceX.
Just this Monday, VCX announced a new investment: Erebor Bank, a chartered national bank for tech startups founded by Palmer Luckey. The bank aims to fill the lending void left by the collapse of Silicon Valley Bank. It's the kind of forward-looking, niche investment that fits the fund's "innovation" mandate.
The Ticking Time Bomb: The September Lockup
Perhaps the most ominous part of Citron's report looks to the future. The firm warns of a potential wave of selling pressure waiting to hit VCX. Why? Because the fund has a retail-heavy shareholder base, and about 100,000 of those investors are currently in a lockup period. They literally cannot sell their shares until September.
Citron's warning is direct: "When that lockup expires, they will all be looking at the same exit at the same time." The image it paints is of a crowded theater with everyone heading for a single door. If even a fraction of those investors decide to cash out, it could create significant downward pressure on the stock, independent of what the underlying companies are doing.
So, you have a fund that offers a rare gateway to hot private companies, now trading at half its price from yesterday. You have a short seller alleging a valuation fantasy, raising ethical questions about marketing, and pointing to a potential shareholder exodus later this year. For investors in VCX, Thursday wasn't just a bad day—it was a crash course in the harsh realities that can hit even the most innovative of investment vehicles.
